Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930050 | 0.88 | ALDH1A1 (0.38) | MAPTL3MBTL1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL4999364 | 0.82 | CTSD (0.39) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14029889 | 0.80 | KMT2A (0.45) | MAPTL3MBTL1LMNANPC1HPGD | |
| SCHEMBL1018574 | 0.79 | CHEK1 (0.41) | MAPTL3MBTL1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14930787 | 0.77 | CYP3A4 (0.51) | LMNASMN1; SMN2BACE1 | |
| SCHEMBL1019040 | 0.77 | P2RX3 (0.41) | MAPTLMNAHPGDALDH1A1POLB | |
| SCHEMBL31425472 | 0.77 | P2RX3 (0.41) | MAPTLMNAHPGDALDH1A1POLB | |
| SCHEMBL14381333 | 0.76 | P2RX3 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL14029802 | 0.76 | GAA (0.53) | MAPTLMNANPC1HPGDRAB9A | |
| SCHEMBL5002661 | 0.75 | KMT2A (0.47) | MAPTL3MBTL1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | MAPT 2935/4885L3MBTL1 2011/4885LMNA 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.